Kidney cancer trials
Into the causes, detection, diagnosis, and treatment of kidney cancer is now being done at many medical centers, university hospitals, and other institutions across the ists are studying several genes that seem to play a part in changing normal kidney cells into renal cell carcinoma (rcc). This allows other genes such as the hypoxia-inducible factor (hif) gene to be activated when they shouldn’t be, which drives a cell toward being cancerous. This information can also be used to develop new e chemotherapy is not very effective against advanced kidney cancer, targeted therapies are now usually the first-line option to treat kidney cancers that cannot be removed by surgery or have spread outside the kidney. Clinical trials are now under way to see if combining these drugs, either with each other or with other types of treatment, might be better than using them potential roles of giving targeted drugs before surgery (called neoadjuvant therapy) are also being studied. The hope with these studies is to shrink tumors to allow for less extensive surgery, prevent cancer spread and hopefully improve cure rates. This could also help people retain more of their normal kidney potential roles of giving targeted drugs after surgery (called adjuvant therapy) are also being studied. The hope with these studies is to see if patients at high risk would benefit from taking certain targeted drugs after their kidney cancer surgery to reduce the chances of the cancer coming back. Researchers are looking for which factors might make a person's cancer more likely to respond to a certain medicine. Some cancers are very aggressive, while others can be very slow growing and last for many years. The way a tumor behaves depends on the specific type of kidney cancer it is. Given this, scientists are looking to see if they can more accurately predict how long someone with kidney cancer may live by testing the kidney cancer for specific traits. Many factors of the cancer cell are looked at and a “score” is given to indicate how fast or slow the cells are growing. More studies are being done in this cancer seems to be one of the cancers most likely to respond to immunotherapy, which is treatment that boosts the body’s immune response against cancer cells. Basic research is now being directed toward a better understanding of the immune system, how to activate it, and how it reacts to american cancer society medical and editorial content team is made up of doctors and master’s-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical an cancer society. We review all feedback and work to provide a better you need immediate assistance, please call 1-800-227-2345, any time day or you would like to unsubscribe/opt out from our communications, please follow this link:Research into the causes, detection, diagnosis, and treatment of kidney cancer is now being done at many medical centers, university hospitals, and other institutions across the ists are studying several genes that seem to play a part in changing normal kidney cells into renal cell carcinoma (rcc). Basic research is now being directed toward a better understanding of the immune system, how to activate it, and how it reacts to iconicon indicating subtraction, or that the element can be iconicon indicating addition, or that the element can be (down) arrow icon, usually indicating that the containing element can be opened and cancer (renal cell cancer). Cancer cancer risk factors & cancer cancer iconicon indicating subtraction, or that the element can be iconicon indicating addition, or that the element can be (down) arrow icon, usually indicating that the containing element can be opened and y for kidney herapy & targeted therapy for kidney ion therapy for kidney beyond kidney cancer clinical cancer cancer clinical d arrow iconan arrowing pointing forward, usually indicating forward movement, or the ability the share something via social iconan icon showing an uppercase letter "x", indicating that this will close the current ok iconan icon representing the facebook social media r iconan icon representing the twitter social media in iconan icon representing the social media service pe iconan icon showing an envelope, usually indicating r iconan icon showing a printer, indicating the ability to print the associated two amazing patients — bill cirelli and daryl palmer — who benefited from targeted therapies for advanced kidney cancer and the memorial sloan kettering team who helped s at memorial sloan kettering are constantly working to improve treatment for kidney cancer through clinical trials. They may also give you additional options if your cancer has returned after standard doctors lead a large number of clinical trials that test new drugs and drug combinations, surgical and radiation therapy techniques, innovative diagnostic technologies, and strategies for preserving quality of life during and after treatment. Phase i study of hdm201 in patients with advanced cancers and a normal tp53 es: colorectal cancer, colon cancer, rectal cancer, germ cell tumors, hematologic malignancies, myelodysplastic syndrome, kidney cancer, leukemia, melanoma, osteosarcoma, soft tissue ons: new york city. Phase i study of lirilumab plus nivolumab immunotherapy in patients with advanced solid es: colorectal cancer, colon cancer, rectal cancer, kidney cancer, lung cancer, non-small cell, melanoma, ovarian ons: new york city. Phase i/ib study of immunotherapy with cpi-444 alone and with atezolizumab in patients with metastatic solid es: bladder cancer, breast cancer, colon cancer, rectal cancer, head & neck cancer, kidney cancer, lung cancer, non-small cell, melanoma, mouth cancer, salivary gland ons: new york city. Phase i/ii study of immunotherapy with medi0680 (amp-514) alone or in combination with medi4736 in patients with advanced kidney es: kidney ons: new york city, westchester. Phase i/ii study of trametinib in children and adolescents with solid es: germ cell tumors, liver cancer, kidney cancer, neuroblastoma, pediatric brain tumors, osteosarcoma, ewing sarcoma, rhabdomyosarcoma, soft tissue sarcoma, wilms' ons: new york city. Phase i/iia study of bms-986218 with or without nivolumab immunotherapy in patients with advanced solid es: breast cancer, kidney cancer, lung cancer, melanoma, gastric cancer, pancreatic ons: new york city. Phase ia/ib study of immunotherapy with mtig7192awith or without atezolizumab in patients with advanced es: bladder cancer, breast cancer, colon cancer, head & neck cancer, kidney cancer, lung cancer, non-small cell, melanoma, mouth cancer, ovarian cancer, salivary gland cancer, gastric ons: new york city. Phase ii study of everolimus for previously untreated sporadic angiomyolipomas of the es: kidney ons: new york city, commack, basking ridge, westchester. Phase ii study of gemcitabine and cisplatin before surgery in patients with high-grade upper tract urothelial es: kidney ons: new york city, commack, basking ridge, rockville centre, westchester, monmouth. Phase ii study of lenvatinib and pembrolizumab immunotherapy in patients with recurrent or persistent endometrial or kidney es: kidney cancer, uterine (endometrial) ons: new york city, patient –fri, 8:30 am–5:30 pm, ntly asked questions about clinical ng up myths and misconceptions about clinical to main with cancer - clinical -of-the-kidney clinical -of-the-kidney clinical al trials for kidney ation provided by who international clinical trials clinical trials below are relevant to kidney cancer. For all clinical trials, go to clinical trials list shows clinical trials for kidney additional conditions and result filtersrecruitment statusall trialsonly trials recruiting nowtrials for children:all trialsonly trials for children under 18 yrscountry of trial:to choose more than one country, hold the ctrl key and click on another a (plurinational states of). Have searched for the following health organisation clinicals scans of blood vessel changes caused by bevacizumab alone or given together with interferon alpha-2a in treating patients with stage iii or stage iv kidney cancer. Phase iii randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial ic resonance imaging-targeted biopsy compared to standard trans-rectal ultrasound guided biopsy for the diagnosis of prostate cancer in men without prior prognostic markers in renal ting the biological effects of pre-operative intravenous administration of jx-594 (thymidine kinase-deactivated vaccinia virus plus gm-csf) prior to planned surgical resection of locally advanced/poor prognosis or metastatic study: comparing ablation with active surveillance, in the management of incidentally diagnosed small renal tumours: a feasibility of genes and environment in patients with cancer in east anglia, trent, or west midlands regions of the united ar targeted photodynamic therapy t1a renal cell® in patients with advanced cancers.
Study of ro7198457 (personalized cancer vaccine [pcv]) as a single agent and in combination with atezolizumab in participants with locally advanced or metastatic linksnhs choices linkskidney healthliving with cancercare and support guidefind cancer support servicesexternal linkskidney cancer ukkidney research uk: kidney cancermy cancer treatment: local nhs us reach $1,000,000! Match my promise of therapy by cancer of cancer ific ing all g to make a difference in the lives of all affected by e immunotherapy discoveries, treatment approvals and our is therapy by cancer immunotherapy e patient a clinical you participate? And the immune system: the vital 's new in to cancer: the cri therapy patient summit of cancer more about this revolutionary cancer tand the a clinical clinical trials that match your diagnosis, stage and treatment ific ctoral & laboratory integration program (clip). Maria kellen clinical immunotherapy e of therapy by cancer immunology research e immunotherapy discoveries, treatment approvals and our scientific the cri scientists committed to the development of therapy for kidney are crihomeimmunotherapy by cancer 's spread the word about immunotherapy! Click to share this page with your d news & makes immunotherapy a promising treatment for kidney cancer? By: elke jäger, nhaus nordwest, frankfurt, 2016 alone, approximately 63,000 new cases of kidney cancer will be diagnosed, with 14,000 deaths. Kidney cancer, more common in men than in women, most frequently occurs in people over the age of 55. Though surgery is the typical treatment for most kidney cancers, also referred to as renal cell cancers, this disease is often resistant to both chemotherapy and radiation treatments. For this reason, more targeted immunotherapies are crucial components of advanced renal cell cancer ully, numerous targeted therapies are fda-approved for treatment of advanced renal cell cancer, making these targeted therapies the most often first treatment method for advanced stages of kidney cancers. Yet another immunotherapy, the checkpoint inhibitor nivolumab, was approved by the fda to treat kidney cancer that has become metastatic, with chemotherapy typically only used after this and other targeted therapies and immunotherapies have been fact, cytokine immunotherapies have been used to treat kidney cancer for over ten years. Beyond cytokines and targeted therapies, several other newer immunotherapy treatments are becoming more prominent in the field of kidney cancer therapy, including checkpoint inhibitors and immune modulators, cancer vaccines, adoptive cell therapy, monoclonal antibodies, cytokines, and adjuvant immunotherapies. Many of these kidney cancer immunotherapies are still undergoing clinical testing, but their successful application in the cases of numerous other cancer types is a promising development for the future use of immunotherapy to treat kidney cancer is one of the major cancer types for which immunotherapy treatments are being developed in preclinical studies and clinical trials. As many currently available renal cell cancer treatments produce less then optimal results, enrolling in a kidney cancer clinical trial may be a safe choice for patients affected by the tly available treatments for kidney cancer are less than optimal. Therefore, enrolling in a clinical trial is often the best and safest option for patients with kidney you a patient or caregiver interested in learning more about cancer immunotherapy treatment and clinical trials? If so, visit our patient section on immunotherapy for kidney 's impact on kidney hout our history, the cancer research institute has supported the best scientists in the field working toward the improvement of kidney cancer treatment, including financial support of research on il-2 and interferon to current treatment approaches using checkpoint blockades. Cri also funded a clinical trial of interferon-alpha in human patients in 1978, work that demonstrated kidney cancer's sensitivity to interferon—paving the way for treatment's approval by the 1993, preclinical studies showed that a vaccine from genetically modified and irradiated tumor cells could activate more powerful and longer-lasting anti-tumor immunity when tested on mice. Based on these promising laboratory findings, cri provided financial support for a phase i clinical trial test of the vaccine in patients with metastatic renal cell carcinoma, leading to the creation of gvax, a therapeutic cancer 1999, cri-funded researchers used serex technology in identifying tumor-related antigents in patients with renal cell carcinoma, providing a solid foundation for the theory that renal cancer could be immunogenic—recognizable by the human immune 2010, several cri researchers successfully completed a phase i study that showed a monoclonal antibody could induce frequent tumor regressions in renal cancer, among other cancer types, with low toxicity rates. Pd-1 blockade was thus established as a promising new treatment for several cancers for which previously approved therapies are not adequately 2012, cri awarded a clinic and laboratory integration program (clip) grant to a scientist studying the metabolism of kidney cancer cells and their surrounding immune system cells. As kidney cancer shares this need for glucose, competition exists that would suggest the effectiveness of manipulation of glucose metabolism. This study also suggests that therapies designed to block immune checkpoints may be found to be more competent when shifting this metabolic competition in favor of the immune cells was brutal, but i was prepared…i bounced back very ia | diagnosed therapy has the potential to cure kidney cancer immunotherapy for patients and e the science of immunotherapy and kidney ng the future of cancer a science-first organization dedicated to supporting cancer immunotherapy research, we're funding a future that fights back against cancer—all with your help. 25 millionawarded in 120clinical trials t our mission to cure all cancers, for a team cri by supporting our many dedicated t the intimates gives to cancer immunotherapy t cell immunotherapy approved for non-hodgkin therapy patient summit – therapy patient summit – ech and bruce ratner to receive 2017 oliver r. Grace ng the way cancer is treated and tand the basics of more about our e the science of immunotherapy. Of clinical of clinical d october 23, addition to the therapies approved by health canada, patients may be able to access several other therapies through clinical trials. Also, clinical trials often give you another option in your treatment cancer canada makes every effort to be aware of major clinical trials for renal cell carcinoma across canada. As a patient with renal cell carcinoma, you may be eligible to access a therapy through a clinical trial depending upon:Your sub-type of kidney cancer (e. You have had one or more prior ease of reference, we have organized major clinical trials into groupings below according to where you are on the treatment journey. For example, you’ll find trials for patients who have just recently been diagnosed and are pre-surgery or clinical trials for those for patients who have already had several systemic stic / imaging stic trials look at what tests (such as blood, laboratory or imaging tests), or procedures are best at finding (detecting) kidney cancer or seeing if kidney cancer has come back (recurred). Also, if the clinical trial is for a particular type of cancer it will be id: st-enhanced ultrasound to evaluate complex renal study is looking at whether an imaging technique, called contrast-enhanced ultrasound (ceus), can be used to accurately view complex kidney (renal) cysts. Complex kidney cysts can have many, thickened or irregular walls and may contain areas of calcification, which is a build up of calcium. Joseph’s healthcare id: st-enhanced ultrasound for follow-up after radiofrequency ablation (rfa) of kidney study will be looking at whether a different technique, called contrast-enhanced ultrasound (ceus), can be used to effectively follow patients who have had radiofrequency ablation (rfa) treatment for a kidney lesion or kidney tumour. At this time, follow-up after treatment involves the patient having ct scans (or mris) over time to see if their kidney cancer has come back (recurred).
Study of muscle energy metabolism in patients with renal cell cancer (rcc) treated with study will use a special type of scan (called technetium-99m sestamibi) to study fatigue in kidney cancer patients taking sunitinib (sutent®). Find out more about this al | cancer pal cancer id: g study in patients with cancer of the head and neck, lung, renal cell, brain, lymphoma and neuroendocrine study is looking at the safety and effectiveness of pet scanning using a special pet tracer called 18f-faza, in patients with different types of cancer including kidney cancer. A positron emission tomography scan (or pet scan) uses a special dye to help find cancer cells in the body. Study to demonstrate the safety and efficacy of 18f-flt in patients with solid tumours or is a study to see how safe and effective imaging with the radiotracer 18f-flt and pet scanning is in patients with a number of known or suspected solid tumours, including kidney cancer. Imaging and measuring cell growth with 18f-flt may be helpful to monitor how a kidney cancer patient has responded to treatment. Find out more about this al | cancer pal cancer stic / predictive s may be done to look at certain factors or characteristics of a patient or their cancer cells that provide information on the likely outcome (prognosis) of a patient with kidney cancer. Studies may also be done to see what might predict how a kidney cancer patient will respond to treatment (predictive factor). Also, if the clinical trial is for a particular type of cancer it will be cancer type: clear id: ctive validation of circulating tumour cells and circulating endothelial cells as biomarkers in clear cell kidney ating tumour cells (ctcs) have prognostic value in many tumour types and may help researchers better understand and address how patients respond to treatment or why their tumour becomes resistant to certain treatments. This study will look at a new ctc technology to study metastatic clear cell kidney cancer with the hope that it can give better information and help improve the treatment of patients with this type of kidney cancer. Find out more about this al | cancer pal health sciences surveillance surveillance uses a watch-and-wait approach, keeping a close watch on a patient’s kidney cancer, but waiting to start treatment until it starts to grow or cause : when available, the researcher in charge of the study, called the principal investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be id: natural history of small renal kidney (renal) masses are less than 4 cm. Most small kidney masses grow slowly and might not need treatment right away, while some grow quickly and should be treated. Researchers will use imaging studies and tissue tests to try to find out which kidney masses are more likely to grow and behave more aggressively and should be treated. Find out more about this al | cancer pal ss margaret cancer centre | university health ve treatment ve therapies, or tumour ablation techniques, are treatments that destroy kidney cancer cells in a certain way. For example, thermal ablative procedures use extreme temperatures such as heat or cold to destroy cancer : when available, the researcher in charge of the study, called the principal investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be id: nct01720706. Study of thermal ablation for treating larger liver and kidney study is looking at how safe and effective a newer way of giving radiofrequency ablation (rfa) treatment is compared to the standard rfa to treat larger tumours in the kidney or liver. Find out more about this al | cancer pal ss margaret cancer centre | university health surgery (neoadjuvant) treatment uvant trials test whether certain treatments given before the main treatment, which is usually surgery, help reduce the size of kidney tumours. Also, if the clinical trial is for a particular type of cancer it will be are no clinical trials for this category at this y to remove the tumour is the mainstay of treatment of kidney cancer treatment. Surgery trials test new ways of doing kidney cancer surgery or new devices or technologies to use during surgery to help protect kidney : when available, the researcher in charge of the study, called the principal investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be are no clinical trials for this category at this surgery (adjuvant) treatment purpose of adjuvant trials is to find out whether additional treatment given after kidney cancer surgery – which is the main treatment for kidney cancer - helps slow or reduce the risk of cancer coming back. Also, if the clinical trial is for a particular type of cancer it will be cancer type: clear cell or id: nct03024996. Study of atezolizumab as adjuvant therapy in patients with kidney cancer at high risk of developing metastasis after a nephrectomy (also called immotion010). Study is looking at how safe and effective a drug called atezolizumab (mpdl3280a, tecentriq®) is when given after surgery for kidney cancer (nephrectomy). This trial is for patients with kidney cancer who are considered to have a high risk of their cancer coming back (recurring) or spreading (metastasizing) after nephrectomy surgery. Find out more about this al | cancer pal cancer agency - centre for the southern baker cancer nski cancer centre | hamilton health hospital cancer cancer centre | sunnybrook health sciences ss margaret cancer centre | university health universitaire de santé mcgill | mcgill university health centre - glen hospitalier universitairede sherbrooke - chus. Pital hotel-dieu de qué health sciences cancer type: clear cell component with or without sarcomatoid id: nct03142334. Study is looking at how safe and effective the drug pembrolizumab (keytruda®, mk-3475) is when given after surgery for kidney cancer (nephrectomy). This trial is for patients with kidney cancer who are considered to have an intermediate to high risk of their cancer coming back (recurring) or spreading after nephrectomy surgery. Tel-dieu de lévis - (cisss) de chaudièion treatment ion therapy trials test different ways of giving radiation or combining radiation with other cancer treatments to better treat patients with kidney : when available, the researcher in charge of the study, called the principal investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be cancer type: clear id: tactic radiotherapy for metastatic kidney cancer being treated with sunitinib (also called ozm-053 study).
This study will measure how well srt can destroy tumours in patients taking the targeted therapy sunitinib (sutent®) for their kidney cancer. Find out more about this al | cancer pal christian baker cancer cancer nski cancer centre | hamilton health sciences health sciences hospital cancer cancer centre | sunnybrook health sciences georg bjarnason &dr patrick ss margaret cancer centre | university health network. Pital général juif | jewish general universitaire de santé mcgill | mcgill university health health sciences cancer type: clear id: ing radiosurgery and nivolumab (opdivo®) to treat brain study is assessing the effect of combining stereotactic radiosurgery (srs), which is radiation given in a more focused and precise way, with an immuno-oncology drug called nivolumab (opdivo®) to treat kidney cancer patients when their cancer has spread to the brain (brain metastases). Researchers want to see if nivolumab and srs can trigger an immune reaction in patients with clear cell kidney cancer and reduce new brain metastases from developing. Find out more about this al | cancer pal hospitalier de l'université de montréal (chum). This study is looking at what side effects and how well 5 treatments of sbrt work in patients with solid tumours (including kidney cancer) whose cancer has spread to a limited number of areas such as the lung, bone, liver or adrenal gland, but not within the skull (extra-cranial). Find out more about this al | cancer pal ss margaret cancer centre | university health id: evaluating the integration of hypofractionated renal ablative radiation therapy in patients with metastatic kidney hypofractionated radiation therapy, the total dose of radiation is divided into larger doses, but treatments are given over a shorter period of time. This study is looking at the safety, side effects and how well this type of treatment works in patients whose kidney cancer has spread (metastasized). Find out more about this al | cancer pal health sciences belal ahmad & dr george cancer type: clear cell id: nct02599779. Proof of principle study of the activity of pembrolizumab given in combination with stereotactic body radiation therapy (sbrt) in patients with tyrosine kinase inhibitor (tki) refractory metastatic kidney cancer, or mrcc (also called ozm-065 study). Sbrt will be given with pembrolizumab to see how well this combination of treatments works in patients with metastatic kidney cancer. Find out more about this al | cancer pal christian baker cancer ss margaret hospital | university health cancer centre | sunnybrook health sciences hospital cancer id: ment of quality of life and outcomes in patients treated with stereotactic body radiation therapy (sbrt) for primary renal cell carcinoma (also called aquos-rcc study). This study will be looking at the quality of life (qol) and outcomes in patients receiving sbrt treatment for their kidney cancer. Find out more about this al | cancer pal cancer centre | sunnybrook health sciences nski cancer centre | hamilton health sciences treatment trials test a new drug, different combinations of drugs, or using different dosages and schedules for giving drugs to better treat patients with kidney cancer. Drug trials also test how safe, effective and what side effects a new drug or combination of drugs may e most kidney cancers do not respond well to chemotherapy, these studies often focus on using new or different combinations of drugs, such as targeted or immuno-oncology therapies. The studies listed below are mainly for patients whose cancer has spread from where it started in the kidney to nearby tissue or lymph nodes (locally advanced) or spread to other parts of the body (metastatic) kidney : when available, the researcher in charge of the study, called the principal investigator, is listed. Also, if the clinical trial is for a particular type of cancer it will be for patients who have not had any previous drug for patients who have had previous drug for patients who have not had any previous drug cancer type: clear cell or non-clear id: nct02853344. Study is for patients with locally advanced or metastatic (stage iv) or recurrent, clear cell or non-clear cell types of kidney cancer, who have never had any previous systemic (drug) treatment for their kidney cancer. This study will be looking at how safe and effective pembrolizumab is in kidney cancer. Find out more about this al | cancer pal cancer nski cancer centre | hamilton health sciences cancer centre | sunnybrook health sciences ting - non clear patients only at this ss margaret cancer centre | university health canada – we do not have a list of all participating centres. Talk to your doctor if you would like more information about this cancer type: clear cell id: nct02684006. Study of avelumab given with axitinib compared to sunitinib in patients with advanced (or metastatic) kidney cancer (also called javelin renal 101 study). This study is for patients with advanced or metastatic kidney cancer, who have not had any prior drug treatment. Find out more about this al | cancer pal cancer agency | sindi ahluwalia hawkins centre for the southern cancer baker cancer centre and foothills medical health sciences cancer centre | sunnybrook research institute. Study is for patients with locally advanced or metastatic (stage iv) kidney cancer, who have never had any previous systemic (drug) treatment for their kidney cancer. This study will look at how safe and effective pembrolizumab and axitinib are when used together compared to sunitinib treatment by itself as an initial treatment in patients with kidney cancer. Find out more about this al | cancer pal nski cancer centre | hamilton health canada – we do not have a list of all participating centres. Study to test combination (immuno-oncology drug) treatments in patients with advanced kidney cancer (also called fraction-rcc). This study does not specify if it is for kidney cancer patients who may or may not have had prior drug treatments, so please check with your doctor to see if this trial might be an option for you. Mclaughlin durham regional cancer ss margaret centre | university health nski cancer centre | hamilton health sciences centre. Ptial hôtel-dieu de québec - ii health sciences centre | cancer care nova cancer type: clear cell id: nct02811861.
Study to compare the effectiveness and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone as a first-line treatment of patients with advanced kidney cancer (also called the clear study). Study is for patients with advanced kidney cancer who have not had any prior drug treatment. Find out more about this al | cancer pal regional cancer g; opening cancer type: clear cell component and/or sarcomatoid id: nct03063762. Study to check the safety, drug action and effectiveness of ro6874281 as a combination therapy in patients with unresectable advanced and/or metastatic kidney cancer (rcc). Study is for patients with advanced or metastatic kidney cancer who have not had any prior drug treatment for their kidney cancer and are not able to have surgery. Find out more about this al | cancer pal ss margaret cancer centre | university health for patients who have had previous drug id: lizumab and ziv-aflibercept in treating patients with advanced solid study is looking at the safety, side effects and best dose of a drug called ziv-aflibercept (zaltrap®), when given along with pembrolizumab (mk-3475, keytruda®) to treat patients with advanced solid tumours. Patients who have had at least 1 prior targeted therapy with a vegf tki for their kidney cancer can take part in this study. Find out more about this al | cancer pal ss margaret cancer centre | university health philippe l. Cancer type: id: ntinib-s-malate, crizotinib, volitinib, or sunitinib malate in treating patients with locally advanced or metastatic kidney cancer (also called papmet study). Study is looking at how effective cabozantinib (cometriq®, bms-907351), or crizotinib (xalkori®), or volitinib (azd6094, savolitinib), or sunitinib (sutent®) each is in treating patients with papillary kidney cancer that is locally advanced or has metastasized. Patients may have had prior surgery, 1 prior systemic (drug) therapy or prior radiation therapy for advanced or metastatic kidney cancer. Find out more about this al | cancer pal cancer baker cancer regional cancer cancer centre | sunnybrook health sciences hospital and cancer health sciences centre | capital district health cancer type: clear and non-clear id: nct02639182. Study of a drug called ags-16c3f compared to axitinib in patients with metastatic kidney -16c3f is an experimental immuno-oncology drug. This study is for patients whose cancer continues to grow and they have had at least 2 prior drug therapies (for clear cell kidney cancer), or 1 prior drug therapy (for non-clear cell kidney cancer) and one of drugs was a targeted therapy with a vegf inhibitor. This study is looking at the safety and how effective ags-16c3f is when given by itself, compared to axitinib in patients with metastatic kidney cancer. Find out more about this al | cancer pal centre for the southern cancer baker cancer nski cancer centre | hamilton health sciences health sciences id: nct02655822. Study to evaluate the safety and anti-cancer activity of a drug called cpi-444 given by itself and also in combination with another drug, called atezolizumab, in patients with advanced study is looking at the safety and effectiveness of cpi-444, an experimental immuno-oncology drug when given by itself or along with atezolizumab (mpdl3280a, tecentriq®), which is also an immuno-oncology drug. Patients may have had 1, but not more than 5 prior drug therapies for advanced, recurrent or progressing kidney cancer. Find out more about this al | cancer pal cancer nski cancer centre | hamilton health sciences hospital cancer id: and effectiveness of a drug called lag525, used by itself and in combination with another drug called pdr001, in patients with advanced 525 and pdr001 are experimental immuno-oncology drugs. This study is looking at safety, effectiveness and dosing of these drugs in patients with solid tumours including kidney cancer. Patients with advanced or metastatic kidney cancer, who have at least 1 measurable lesion or mass and whose cancer has continued to grow despite prior treatment may take part in this study. Find out more about this al | cancer pal ss margaret cancer centre | university health is investigative site - we do not have a list of participating centres. Study of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumours with liver study is looking at the side effects and best dose of romidepsin (istodax®) to use to treat patients with various cancers. Patients with advanced, metastatic or recurrent kidney cancer and moderate or severe liver function problems may take part in this study. This study is for patients whose kidney cancer continues to grow or has come back (recurred) despite having standard treatments. Romidepsin is a chemotherapy drug used to treat certain types of lymphoma and may stop the growth of cancer cells by blocking the activity of proteins that are important for cancer cells to grow and survive. Find out more about this al | cancer pal ss margaret cancer centre | university health cancer type: renal medullary cancer or rhabdoid tumours of the id: of the ezh2 inhibitor tazemetostat in patients with ini1-negative tumours or relapsed/refractory synovial study is looking at the side effects, safety and effectiveness of an experimental drug called tazemetostat (epz-6438), in patients with the uncommon types of kidney cancer – medullary and rhabdoid. Tazemetostat is a drug that targets and kills certain cancer cells by stopping a gene called ezh2 from working. This study is for patients with metastatic kidney cancer for which there are no standard therapies available and their cancer has relapsed or is no longer responding to treatment (is refractory). Find out more about this al | cancer pal cancer ss margaret cancer centre | university health network. Cancer type: clear id: 0128 and mln0128 plus mln1117 compared with everolimus in the treatment of adults with advanced or metastatic kidney study is testing the safety and effectiveness of two new experimental drugs called mln0128 and mln1117.
Mln0128 and mln1117 are being tested to treat people with clear cell kidney cancer that is advanced or has spread to other parts of the body (metastasized). Patients may have had 1, but not more than 4 prior drug treatments for their kidney cancer. Patients will get either mln0128 only, mln0128 and mln1117, or everolimus (afinitor®), find out more about this al | cancer pal cancer institute. This study is looking at safety, effectiveness and dosing of these drugs in patients with kidney cancer. Patients with advanced or metastatic cancer, who have at least 1 measurable lesion or mass, have had treatment for their kidney cancer and can no longer tolerate it, or their cancer has continued to grow despite prior treatment may take part in this ts will get either mbc453 only, or mbg453 with pdr001. Find out more about this al | cancer pal ss margaret cancer centre | university health is investigative site - we do not have a list of participating centres. Talk to your doctor if you would like more information about this cancer type: clear id: and effectiveness of lenvatinib in combination with everolimus in patients with kidney trial is looking at the safety and effectiveness of 2 different doses of lenvatinib when given along the drug everolimus for patients with clear cell kidney cancer. Lenvatinib (lenvima®) is a type of tyrosine kinase inhibitor targeted therapy that may block signals that allow cancer cells to grow and multiply, and may also block the ones that help blood vessels grow. Everolimus (afinitor®) is also a targeted therapy, but it is an mtor inhibitor, so it works by blocking a certain protein that is important for cancer cells to grow, divide and survive. This study is for patients with advanced clear cell kidney cancer, who have 1 prior drug treatment for their kidney cancer, namely a vascular endothelial growth factor (vegf)-targeted treatment. Find out more about this al | cancer pal baker cancer cancer type: clear id: nct02089685. Study to evaluate the safety and effectiveness of pembrolizumab (mk-3475) in combination with pegylated interferon alfa-2b and pembrolizumab with ipilimumab in patients with advanced kidney cancer (also called mk-3475-029 or keynote-29 study). Study is being done to see how safe, effective and how a patient with advanced or metastatic kidney tolerates the drug combination of pembrolizumab and pegylated interferon alfa-2b (pegifn-2b) compared to the drug combination of pembrolizumab and ipilimumab. This study is for patients with advanced or metastatic clear cell kidney cancer, who have been had at least 1 prior drug treatment for their kidney cancer. Find out more about this study,Hospital | cancer pal canada – we do not have a list of all participating centres. Talk to your doctor if you would like more information about this id: escalation and expansion study of nktr-214 in combination with nivolumab in patients with advanced or metastatic kidney cancer (also called pivot-02). Study is being done to find out the dose of nktr-214 to given when used with nivolumab (opdivo®), and then also to see how safe, effective and how a patient with advanced or metastatic kidney tolerates the drug combination of nktr-214 and nivolumab. Both drugs target the immune system and may work together to better work against cancer. Nivolumab is an immune-oncology drug, an anti pd-1 drug that used as a second-line treatment for kidney cancer in canada. This study if for patients with kidney cancer who have had 1 prior anti-angiogenic drug therapy, but they cannot have had prior immuno-oncology treatments. Find out more about this al | cancer pal hospital and cancer cancer centre | sunnybrook health sciences ss margaret cancer centre | university health network. Study to test combination (immuno-oncology) drug treatments in patients with advanced kidney cancer (also called fraction-rcc). Ptial hôtel-dieu de québec - ii health sciences centre | cancer care nova id: investigational immuno-therapy study to assess the safety, tolerability and effectiveness of an anti-lag-3 (relatlimab)with and without an anti-pd-1 (nivolumab)in the treatment of solid study is for patients with certain types of tumours including kidney cancer that has spread and/or cannot be removed by surgery. Relatlimab and nivolumab are both immuno-oncology drugs, but they work in slightly different ways to improve the body’s immune system to fight cancer. This study is for kidney cancer patients who have not had any prior immune-oncology drug therapy. Find out more about this al | cancer pal ss margaret centre | university health cancer type: clear cell id: nct02627963. Study to compare the drug tivozanib to sorafenib in patients with refractory advanced kidney cancer (also called tivo-3 trial). Study is for patients with metastatic kidney cancer, who have a clear cell component, have had 2 or 3 prior drug therapy treatments and whose cancer is no longer responding to treatment (considered refractory). Find out more about this al | cancer pal christian health sciences cancer centre | sunnybrook health sciences . Please register with kidney cancer canada and join the discussion forum to reach out to other patients participating in a clinical trial or to ask a specific i join a clinical trial? Canadian urological association (cua) endorses kidney cancer canada and its mission; this does not necessarily equate to endorsement of this website's : sputnik design partners development: envision online media inc.